Haley Addis, Pharm.D, Vice President, Clinical Resource & Account Management, was recognized among Women Leaders in Supply Chain by the Journal of Healthcare Contracting. Addis shares her thoughts on what makes a successful supply chain leader in today’s marketplace.
Nathan Overton, HealthTrust Director of HCA Healthcare Contracting is among the Ten People to Watch in healthcare contracting. Overton explains flexibility in supporting hospitals during COVID.
Stolen healthcare records can have a big financial impact to a hospital system. Terry Moon, AVP of strategic sourcing, IT and cybersecurity talks about why medical records are a big target for hackers.
Fred Keller, HealthTrust VP of Strategic Sourcing and Custom Contracting is named one of the Ten People to Watch in healthcare contracting. Keller develops collaborative relationships with the entire supply chain—from suppliers to end users—as he executes decisions in support of high-quality patient care. See his profile beginning on page 16.
Lynn Cook, CEO of HealthTrust’s Consolidated Service Center in Richmond, Virginia is profiled and explains how the Center provides supply and pharmacy distribution and logistics, purchasing and accounts payable, and more in this unique shared services model supporting healthcare facilities in four states. See Page 13.
Orthopedic surgery requires trust and transparency among stakeholders to foster a collaborative operating environment and informed patient population. InVivoLink provides a platform to streamline the orthopedic surgery process through patient education, an implant registry and outcomes data.
HealthTrust CMO Michael Schlosser, M.D., and four physicians in the Physician Advisors Program, take a look back at a “year of uncertainty” about the first mandatory bundled payment model of CMS for total joint replacements, and a peek ahead at expansion of the experiment in 2017 to bypass surgery and the treatment of heart attacks.
HealthTrust’s Mark Dumond, AVP of Technology Services, discusses the perennial culprits of year-over-year price increases of 5 to 10 percent on medical device technology, most of which lacks the evidence to substantiate the “latest and greatest” claims of manufacturers. The consequences of inaction on cardiovascular service line margins have never been greater.